https://www.gracetx.com/investors/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/acastipharma/files/theme/images/Grace_Logo_RGB.png /investors Equisolve Investor Relations Suite https://www.gracetx.com/investors/news-events/press-releases/detail/303/grace-therapeutics-provides-regulatory-update-on-new-drug-application-for-gtx-104 Thu, 23 Apr 26 13:13:00 -0400 https://www.gracetx.com/investors/news-events/press-releases/detail/303/grace-therapeutics-provides-regulatory-update-on-new-drug-application-for-gtx-104 https://www.gracetx.com/investors/news-events/press-releases/detail/302/grace-therapeutics-announces-abstract-highlighting-strive-on-phase-3-trial-results-accepted-for-presentation-at-aan-2026 Tue, 14 Apr 26 08:00:00 -0400 https://www.gracetx.com/investors/news-events/press-releases/detail/302/grace-therapeutics-announces-abstract-highlighting-strive-on-phase-3-trial-results-accepted-for-presentation-at-aan-2026 https://www.gracetx.com/investors/news-events/press-releases/detail/301/grace-therapeutics-to-present-data-on-the-unmet-medical-needs-and-potential-benefits-of-gtx-104-in-the-treatment-of-asah-at-upcoming-medical-conferences Thu, 19 Mar 26 08:00:00 -0400 https://www.gracetx.com/investors/news-events/press-releases/detail/301/grace-therapeutics-to-present-data-on-the-unmet-medical-needs-and-potential-benefits-of-gtx-104-in-the-treatment-of-asah-at-upcoming-medical-conferences https://www.gracetx.com/investors/news-events/press-releases/detail/300/grace-therapeutics-to-participate-in-the-td-cowen-46th-annual-health-care-conference Wed, 25 Feb 26 08:00:00 -0500 https://www.gracetx.com/investors/news-events/press-releases/detail/300/grace-therapeutics-to-participate-in-the-td-cowen-46th-annual-health-care-conference https://www.gracetx.com/investors/news-events/press-releases/detail/299/grace-therapeutics-announces-third-quarter-2026-financial-results-provides-business-update Thu, 12 Feb 26 08:00:00 -0500 https://www.gracetx.com/investors/news-events/press-releases/detail/299/grace-therapeutics-announces-third-quarter-2026-financial-results-provides-business-update https://www.gracetx.com/investors/news-events/press-releases/detail/298/grace-therapeutics-to-participate-in-16th-annual-craig-hallum-alpha-select-conference Mon, 17 Nov 25 08:00:00 -0500 https://www.gracetx.com/investors/news-events/press-releases/detail/298/grace-therapeutics-to-participate-in-16th-annual-craig-hallum-alpha-select-conference https://www.gracetx.com/investors/news-events/press-releases/detail/297/grace-therapeutics-announces-second-quarter-2026-financial-results-provides-business-update Thu, 13 Nov 25 08:00:00 -0500 https://www.gracetx.com/investors/news-events/press-releases/detail/297/grace-therapeutics-announces-second-quarter-2026-financial-results-provides-business-update https://www.gracetx.com/investors/news-events/press-releases/detail/296/grace-therapeutics-announces-abstract-accepted-for-presentation-at-society-of-vascular-and-interventional-neurology-annual-meeting Tue, 11 Nov 25 08:30:00 -0500 https://www.gracetx.com/investors/news-events/press-releases/detail/296/grace-therapeutics-announces-abstract-accepted-for-presentation-at-society-of-vascular-and-interventional-neurology-annual-meeting https://www.gracetx.com/investors/news-events/press-releases/detail/295/grace-therapeutics-secures-approximately-4-0-million-through-common-warrant-exercises-following-acceptance-of-new-drug-application-for-gtx-104-for-formal-fda-review Thu, 23 Oct 25 08:00:00 -0400 https://www.gracetx.com/investors/news-events/press-releases/detail/295/grace-therapeutics-secures-approximately-4-0-million-through-common-warrant-exercises-following-acceptance-of-new-drug-application-for-gtx-104-for-formal-fda-review https://www.gracetx.com/investors/news-events/press-releases/detail/294/grace-therapeutics-pivotal-phase-3-strive-on-safety-trial-presented-at-2025-neurocritical-care-annual-meeting Mon, 22 Sep 25 08:00:00 -0400 https://www.gracetx.com/investors/news-events/press-releases/detail/294/grace-therapeutics-pivotal-phase-3-strive-on-safety-trial-presented-at-2025-neurocritical-care-annual-meeting